Girish Mahajan (Editor)

Romosozumab

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Type  Whole antibody
Target  Sclerostin
Legal status  Investigational
Source  Humanized (from mouse)
ATC code  none
CAS Number  909395-70-6

Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis.

Romosozumab was originally discovered by Celltech (now owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product's development.

References

Romosozumab Wikipedia


Similar Topics
Ralph Botting
Boniface Tumuti
Neil Fallon
Topics
 
B
i
Link
H2
L